These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18625157)

  • 41. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Guthrie R
    Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation.
    Kleinert S
    Lancet; 1999 Sep; 354(9181):841. PubMed ID: 10485736
    [No Abstract]   [Full Text] [Related]  

  • 46. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation.
    Chaturvedi N
    Lancet; 2000 Jan; 355(9200):246-7. PubMed ID: 10675066
    [No Abstract]   [Full Text] [Related]  

  • 48. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ACE inhibitor reduces cardiovascular events by 22%.
    Indian J Med Sci; 2000 Mar; 54(3):112-4. PubMed ID: 11227615
    [No Abstract]   [Full Text] [Related]  

  • 50. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
    Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose?
    Pellizzer AM; Krum H
    Aust Fam Physician; 1996 Jul; 25(7):1067-9, 1072-3, 1076-7. PubMed ID: 8768273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario.
    Tu K; Mamdani MM; Jacka RM; Forde NJ; Rothwell DM; Tu JV
    CMAJ; 2003 Mar; 168(5):553-7. PubMed ID: 12615747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].
    Oğuz A
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 6():4-12. PubMed ID: 20019467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of ACE inhibitors in the treatment of cardiovascular disease.
    Gums JG
    Am Pharm; 1992 Jun; NS32(6):62-70. PubMed ID: 1615843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using ACE inhibitors appropriately.
    Bicket DP
    Am Fam Physician; 2002 Aug; 66(3):461-8. PubMed ID: 12182524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension.
    Meurin P
    Am J Cardiovasc Drugs; 2006; 6(5):327-34. PubMed ID: 17083267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.